Loading
Life sciences · Journal article
Frontiers in Nutrition · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a diet-related metabolic disorder characterized by hepatic lipid accumulation, dyslipidemia, insulin resistance, oxidative stress, and chronic inflammation, highlighting the need for safe nutritional interventions. Aim This study evaluated the antihyperlipidemic, antioxidant, and anti-inflammatory effects of D-allulose, alone or in combination with dorsomorphin, in a high-fat diet (HFD)-induced rat model of Metabolic dysfunction-associated steatotic liver disease (MASLD). Methods Forty-eight male Wistar rats were allocated to a control diet group, an HFD group, or an HFD group treated orally with D-allulose (0.3 or 0.6 g/kg) with or without dorsomorphin (0.2 mg/kg) orally for 12 weeks. Omnibus 𝑝-values for the 22 biochemical endpoints were subjected to a retrospective Benjamini–Hochberg false-discovery-rate sensitivity analysis. Results HFD feeding induced weight gain, dyslipidemia, hepatic injury, oxidative stress, inflammation, and hyperinsulinemia. D-allulose dose-dependently ameliorated these disturbances, reducing atherogenic lipids, lipid peroxidation, inflammatory cytokines, and insulin while improving antioxidant status. Notably, TG decreased from 164.51 mg dL −1 in HFD rats to 113.52 and 99.43 mg dL −1 with low- and high-dose D-allulose, respectively, while LDL-C decreased from 86.45 to 53.19 and 49.24 mg dL −1; HDL-C remained unchanged. D-allulose also attenuated HFD-induced hepatic steatosis, degeneration, necrosis, inflammation, and early fibrosis, and this histological protection was maintained or enhanced by dorsomorphin co-administration. A retrospective FDR sensitivity analysis supported the principal lipid, antioxidant, inflammatory, and insulin findings, whereas the ALT and FBG findings did not remain significant and were considered exploratory. Conclusion The combination groups generally matched or outperformed D-allulose alone across several biochemical and histological endpoints. However, because dorsomorphin is a non-selective AMPK/BMP inhibitor and AMPK activity was not directly measured, these findings do not establish AMPK’s mechanistic involvement. Overall, D-allulose shows promising protective impacts as a bioactive ingredient for obesity-related metabolic disorders.